INSM

Insmed Incorporated

A maker of inhaled medicines for rare lung diseases, Insmed sells ARIKAYCE for a stubborn bacterial lung infection and BRINSUPRI for bronchiectasis, with gene therapies for muscular dystrophy and ALS in the works. Founded in 1988 in Richmond, Virginia, it began by developing insulin-like growth factor proteins before turning to respiratory care. Its ARIKAYCE was the first drug approved under the FDA's Limited Population Pathway, designed for serious infections in small patient groups.

CUSIP: 457669307HealthcareUS2 holders

Ownership Activity Financials Filings

INSM

INSM

Results of Operations and Financial Condition

Regulation FD Disclosure

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure